EpiBlok aims to change epilepsy treatment by using dynorphins, neuropeptides released during seizures, to target drug-resistant focal epilepsy while minimizing neurotoxicity risks. Read the full article below: www.bioxconomy.com/modalities/d...

Scorpius closed its North Carolina facilities, cut 28% of its workforce, and restructured to address a $297M deficit. Legal issues and financial struggles further impacted the CDMO's operations. Read the full article below: www.bioprocessintl.com/facilities-c...

Eli Lilly plans a $6 billion manufacturing facility in Huntsville, Alabama, focusing on GLP-1 medicines like orforglipron. The site will use AI, ML, and sustainable practices, creating 450 jobs. Read my full article below: www.bioprocessintl.com/facilities-c...

NextCell, a Swedish startup, is using mesenchymal stem cells (MSCs) to halt type 1 diabetes progression in newly diagnosed patients. Their scalable manufacturing process was highlighted at the CGT International Europe event. Read my full article below: www.bioprocessintl.com/therapeutic-...

Alzheimer’s is a devastating disease that affects 24 million people across the globe, but GLPs may be able to offer a solution. A new Phase IIb (NCT01843075) clinical trial has shown liraglutide may be able to slow disease progression. Read my full article below: www.bioxconomy.com/modalities/g...

Politicians on both sides of the aisle have proposed legislation in the US Senate to establish a National Biopharmaceutical Manufacturing Center of Excellence (COE) to boost the country’s biotechnology industry. Read more of my article below: www.bioprocessintl.com/global-marke...

Contract development and manufacturing organization (CDMO) Cellipont announced a partnership with Ronawk, a biotechnology start-up company focusing on the efficient culturing of cells. Read my full article below: www.bioprocessintl.com/upstream-dow...

Major US non-profit Caring Cross announced a collaboration with the Amrita Research Center, based in Delhi, India, to bring the manufacturing of integral cancer therapies to Indian hospitals. Read my full article below: www.bioprocessintl.com/global-marke...

November marked significant milestones and setbacks in the neuromuscular disease landscape. Chief among them was the Food and Drug Administration’s (FDA) approval of Novartis’ Itvisma (onasemnogene abeparvovec). Read my full article below: www.bioxconomy.com/modalities/s...

Last week, UK-based pharmaceutical conglomerate AstraZeneca announced a further $2 billion investment at two separate sites within the US state of Maryland. Read the full article below: www.bioprocessintl.com/bioprocess-i...

Preclinical research shows ASOs could delay retinal degeneration in juvenile Batten’s disease. BioXconomy spoke to study author Michelle Hastings about what her team’s findings could mean for the future treatment of Batten disease. Read my full article below: www.bioxconomy.com/modalities/a...

Earlier this week, a leading pediatric cancer center at Cincinnati Children's Hospital announced it is expanding its facilities with the addition of an Applied Gene and Cell Therapy center. Read my full article below: www.bioprocessintl.com/bioprocess-i...

'Earlier this year, biotechnology company Biomar filed for voluntary bankruptcy proceedings. The company was one of the first institutions to establish itself in the Léon Technology Park in Monterrey, Mexico.' Read more of my article below: www.bioprocessintl.com/facilities-c...